Endotoxin Markers Are Elevated in Adolescents With Obesity With and Without Metabolic Dysfunction‐Associated Steatotic Liver Disease

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease in paediatric patients. Adult and murine studies have suggested a role for endotoxin from gram‐negative bacteria in the development of MASLD, but there is incomplete and conflicting evidence for its role in adolescents.

• Publication year

  2026

• Venue

  Pediatric obesity

• Publication date

  2026-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/ijpo.70093PMID 41667148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations

  2025influential reference
• A Comparison of Novel Serum Markers of Liver Health in Adolescents With Metabolic Dysfunction‐Associated Steatotic Liver Disease

  2025cited by this paper
• Oxidized high‐density lipoprotein and low‐density lipoprotein in adolescents with obesity and metabolic dysfunction‐associated steatotic liver disease

  2024cited by this paper
• Serum adropin is unaltered in adolescents with histology-confirmed steatotic liver disease.

  2024cited by this paper
• Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?

  2024cited by this paper
• Endotoxin biomarkers, hepatic fat fraction, liver volume and liver stiffness among adolescents at high‐risk for non‐alcoholic fatty liver disease: The HEROES study

  2023cited by this paper
• Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease: a systematic review and meta-analysis.

  2022cited by this paper
• The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases

  2021cited by this paper
• Pathophysiology of NASH in endocrine diseases

  2021cited by this paper
• A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.

  2020cited by this paper
• Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.

  2020cited by this paper
• Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease

  2020cited by this paper
• Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?

  2019influential reference
• Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial

  2019cited by this paper
• Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children

  2017cited by this paper
• Pediatric Non-Alcoholic Fatty Liver Disease

  2017cited by this paper
• Multiple gut–liver axis abnormalities in children with obesity with and without hepatic involvement

  2017cited by this paper
• NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

  2017cited by this paper
• Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity.

  2017cited by this paper
• In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis

  2017cited by this paper
• Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis

  2014cited by this paper
• Fructose Induced Endotoxemia in Pediatric Nonalcoholic Fatty Liver Disease

  2014cited by this paper
• Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity.

  2014cited by this paper
• Expansion of the Homeostasis Model Assessment of β-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2

  2013cited by this paper
• Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

  2012cited by this paper
• Carotid intima-media thickness, dietary intake, and cardiovascular phenotypes in adolescents: relation to metabolic syndrome.

  2010cited by this paper
• Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children

  2010influential reference
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Lipopolysaccharide endotoxins.

  2002cited by this paper
• 2000 CDC Growth Charts for the United States: methods and development.

  2002cited by this paper
• Longitudinal study on pubertal insulin resistance.

  2001cited by this paper
• Insulin resistance during puberty: results from clamp studies in 357 children.

  1999cited by this paper
• Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis.

  year unknowncited by this paper

• No citing papers are available for this paper.